Company intelligence / Profile preview

Targovax

Ownership: Private
Employees: ~21
Development stage: Other

Overview

Targovax has multiple clinical programs including TG01 for pancreatic cancer, TG02 for colorectal cancer, and ONCOS-102 for melanoma. The company is transitioning to focus on circular RNA therapeutics while maintaining its immunotherapy programs. TG01 has shown promise in phase 1/2 clinical trials and is currently being tested in pancreatic cancer and multiple myeloma.

Therapeutic areas: Oncology
Modalities: Cancer vaccinesOncolytic virusesCircular RNA (circRNA) therapeutics
Industry: Biotech

Drug pipeline

9 assets

TG01

8 more assets in the full pipeline.

Request access →

Partnerships

Agenus Inc.SOTIO

Beyond the preview

Go deeper on Targovax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Targovax.

Explore the full profile